Competitive ELISA for detection of native <i>ras</i> gene‐related products in sera of cancer patients

Epelbaum, Ron; Bartal, Arie H.; Rivkin, Mila; Tugendhaft, N; Shalitin, Channa

doi:10.1002/jcla.1860030404

Cited by 9 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The function of the p21 protein in cell proliferation in vivo is not known at present. In view of the partial amino-acid homology to bacterial proteins involved in DNA replication or transcription (Friedrich and Kadner, 1987;Weston and Kadner, 1988;Projan and Novick, 1988 ; Table I), it is tempting to speculate that this protein has a function at the cellular level in DNA replication and/or transcription.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A novel 21‐kDa protein as a serum marker for benign and malignant urogenital tumors: Preliminary communication

Shalitin

Epelbaum

Valansi

et al. 1991

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

A novel 21-kDa protein (p21) was isolated from auto-immune complexes, found in sera of 14 patients with malignant urogenital tumors and isolated on Protein A-Sepharose. Isolated complexes were analyzed in 15% polyacrylamide-SDS minigels. After staining with Coomassie blue R, the bands were scanned with a clinical densitometer. The level of p21 in sera of cancer patients was 3 times higher than that found in normal individuals. An attempt was made to correlate consecutive levels of p21 in the sera of these cancer patients with the clinical course. In 4 cases a significant decrease (57-75%) in the level of p21 was observed in parallel with response to treatment. In 9 of 10 cases where no response or tumor progression was observed, the relative abundance of p21 increased or remained unchanged. Thus, the level of p21 was indicative of progression or regression of the disease in 13 out of 14 patients. Similar high levels of p21 in sera were also found in 22 patients with benign hyperplasia of prostate. The p21 protein was not immunoreactive with known anti-ras antibodies such as Y13-259, 142-24E05 and anti-rap1. Partial amino acid analysis of this protein showed no complete homology to any known protein, but a partial homology to known bacterial proteins involved in DNA replication or transcription was observed. Monitoring of the novel p21 levels before and after treatment may be useful in follow-up of cancer patients, providing evidence of response to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…There were no proteins which showed absolute identity, suggesting that this protein may be novel. Table I illustrates the partial sequence homology of p21 peptide to bacterial proteins involved in DNA transcription or replication (Friedrich and Kadner, 1987;Weston and Kadner, 1988;Projan and Novick, 1988).…”

Section: Characterization Of the P21 Proteinmentioning

confidence: 99%

A novel 21‐kDa protein as a serum marker for benign and malignant urogenital tumors: Preliminary communication

Shalitin

Epelbaum

Valansi

et al. 1991

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The mean serum level for the EGFR ECD in the cancer cases (mean ± SD = 636 ± 299 fm/ml) was statistically significantly elevated (p< 0.05) in comparison to the mean level in the asbestosis controls (mean ± SD = 546 ± 147 fm/ml or the nonasbestosis controls (336 ± 228 fm/ml). Seven (76,77). In another study, increased serum p21 by ELISA was found in 3 of 13 (23%) patients with stomach cancer compared to 0 of 3 (0%) normal controls, although no increases were noted in 29 other patients with different cancers (78).…”

Section: Oncoproteins Growth Factor Receptorsmentioning

confidence: 96%

Biomarkers of gene expression: growth factors and oncoproteins.

Brandt‐Rauf

1997

Environ Health Perspect

View full text Add to dashboard Cite

This article reviews the literature on the application of methods for the detection of growth factors, oncogene proteins, and tumor-suppressor gene proteins in the blood of humans with cancer or who are at risk for the development of cancer. The research summarized here suggests that many of these biomarker assays can be used to distinguish between diseased and nondiseased states and in some instances may be able to predict susceptibility for future disease. Thus, these biomarkers could be valuable tools for monitoring at-risk populations for purposes of disease prevention and control. -Environ Health Perspect 105(Suppl 4): 807-816 (1997)

show abstract

“…The p21 ras-related protein was elevated in serum by ELISA in 5 of 34 (15%) patients with early stage malignancies and 26 of 59 (44%) patients with advanced malignancies compared to 1 of 58 (2%) controls, with the highest levels in patients with lymphoma, breast, and urogenital malignancies (76,77). The ras oncogene is activated in carcinogenesis either by overexpression of p21 or by expression of point-mutated forms of p21.…”

Section: Other Oncogene Proteinsmentioning

confidence: 99%